Form 4: AN2 Therapeutics Director and 10% Owner Sells Over 2.5 Million Shares

Braden Michael Leonard, a Director and 10% owner of AN2 Therapeutics, Inc., has reported the sale of 2,532,000 shares of common stock for approximately $2.87 million in late May 2025.

Summary

• Braden Michael Leonard, identified as a Director and 10% Owner of AN2 Therapeutics, Inc. (ANTX), reported multiple sales of common stock.
• On May 28, 2025, Mr. Leonard sold 2,000,000 shares at a price of $1.16 per share, followed by an additional sale of 100,000 shares at the same price.
• On May 30, 2025, he sold 425,000 shares at $1.01 per share and 7,000 shares at an average price of $1.0324 per share.
• The total number of shares sold across these transactions amounts to 2,532,000 shares.
• The total proceeds from these sales are approximately $2,872,476.80.
• Following these transactions, Mr. Leonard's indirect beneficial ownership through BML Investment Partners, L.P. stands at 3,217,432 shares of common stock.
• Mr. Leonard, as the managing member of BML Capital Management, LLC (general partner of BML Investment Partners, L.P.), exercises investment and voting control over these shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner, which can be interpreted as a lack of confidence in the company's future performance or valuation.

Negatives

• Significant insider selling by a Director and 10% owner can be perceived negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects or valuation.
• The sales occurred at prices ranging from $1.01 to $1.16, which might be seen as a low valuation by the insider, especially if the company's long-term outlook is considered strong.

Risks

• The substantial sale of shares by a key insider could lead to negative investor sentiment and potential downward pressure on the stock price.
• Such sales might raise questions among investors regarding the insider's view on the company's future performance or strategic direction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, particularly sales by significant shareholders or directors, are closely watched by the market as they can provide insights into management's perception of the company's value or future prospects. While not uncommon, large sales can sometimes trigger investor concern, especially if not accompanied by clear explanations for diversification or tax planning.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might become more cautious about investing in AN2 Therapeutics given the substantial divestment by a key insider.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Director, 10% Owner, Braden Michael Leonard, SEC Filing